# **Open Access**



# Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64 Years: a model-based decision analysis

Angela R. Wateska<sup>1</sup>, Mary Patricia Nowalk<sup>2</sup>, Richard K. Zimmerman<sup>2</sup>, Kenneth J. Smith<sup>1\*</sup> and Chyongchiou J. Lin<sup>2</sup>

# Abstract

**Background:** Adults aged 18–64 years with comorbid conditions are at high risk for complications of certain vaccine-preventable diseases, including influenza and pneumococcal disease. The 4 Pillars<sup>™</sup> Practice Transformation Program (4 Pillars Program) increases uptake of pneumococcal polysaccharide vaccine, influenza vaccine and tetanus-diphtheria-acellular pertussis vaccine by 5–10% among adults with high-risk medical conditions, but its cost-effectiveness is unknown.

**Methods:** A decision tree model estimated the cost-effectiveness of implementing the 4 Pillars Program in primary care practices compared to no program for a population of adults 18–64 years of age at high risk of illness complications over a 10 year time horizon. Vaccination rates and intervention costs were derived from a randomized controlled cluster trial in diverse practices in 2 U.S. cities. One-way and probabilistic sensitivity analyses were conducted.

**Results:** From a third-party payer perspective, which considers direct medical costs, the 4 Pillars Program cost \$28,301 per quality-adjusted life year gained; from a societal perspective, which adds direct nonmedical and indirect costs, the program was cost saving and more effective than no intervention. Cost effectiveness results favoring the program were robust in sensitivity analyses. From a public health standpoint, the model predicted that the intervention reduced influenza cases by 1.4%, with smaller decreases in pertussis and pneumococcal disease cases.

**Conclusion:** The 4 Pillars Practice Transformation Program is an economically reasonable, and perhaps cost saving, strategy for protecting the health of adults aged < 65 years with high-risk medical conditions

Keywords: High-risk adults, Pneumococcal vaccine, Influenza vaccine, Tdap vaccine, Primary care, Adult vaccination

# Background

Adults aged 18–64 years with immunocompromising and other chronic medical conditions are becoming a sizable proportion of the U.S. population; of U.S. adults aged 50–64 years, 30.6% had a least one of these conditions [1]. These individuals are at high risk for complications of certain vaccine-preventable diseases, including influenza and pneumococcal disease [2]. Yet, vaccination rates among all adults aged 19–64 years are low overall, with influenza vaccination coverage from 31.5–47.7% and tetanus vaccination 62.6–64.7% among all 19–64 year

\* Correspondence: smithkj2@upmc.edu

<sup>1</sup>Department of Medicine, University of Pittsburgh School of Medicine, 200 Meyran Ave., Suite 200, Pittsburgh, PA 15213, USA olds, and pneumococcal vaccination in only 20.3% of high-risk individuals in this age group [3]. Few studies have examined attempts to overcome barriers to vaccine uptake in 19–64 year olds.

A recent exception is the 4 Pillars<sup>m</sup> Practice Transformation Program (4 Pillars Program) which has increased vaccination rates among varied populations in diverse medical practices [4–8]. The program, developed through CDC support and owned and licensed by the University of Pittsburgh, consists of medical practicebased tools to improve: 1) the convenience of vaccination services, 2) communication with patients about the importance of immunization and the availability of vaccines, 3) office systems to facilitate immunization, and 4) motivation through an office immunization champion



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Full list of author information is available at the end of the article

who monitors progress and encourages adherence to vaccination-promoting office practices. Although the 4 Pillars Program (4pillarstoolkit.pitt.edu) requires a commitment to long-term practice systems changes, it has been shown to be cost-effective among adults aged 65 years and older [9], but its cost-effectiveness in highrisk non-elderly adults is unknown.

Using changes in vaccination rates as a result of the 4 Pillars Program, where trial-based vaccination rates in high-risk adults aged 18–64 improved by 5–10%, and cost estimates for implementing the program, we examined the cost-effectiveness of the 4 Pillars Program for improving vaccination rates among adults 18–64 years of age with immunocompromising and other chronic medical conditions that confer a high risk of vaccinepreventable disease. This analysis was motivated, in part, by the modest program-related improvement in vaccination rates carrying with it a relatively high burden of investment.

## Methods

Using a decision tree model (Fig. 1), constructed in TreeAge Pro 2017 (TreeAge Software, Williamstown MA), the cost-effectiveness of implementing the 4 Pillars Program in primary care practices was compared to no program in identical hypothetical cohorts of high-risk adults 18–64 years of age. High-risk adults were defined, using CDC definitions, as those with one or more comorbid or immunocompromising conditions, with comorbid conditions including one or more of the following: chronic heart, lung, or liver diseases, alcoholism, diabetes mellitus, or individuals who smoke cigarettes; immunocompromising conditions were HIV disease, hematologic malignancies, dialysis, nephrotic syndrome, organ or bone marrow transplant, sickle cell disease, immune deficiency, or current immunosuppressive therapy. Pneumococcal polysaccharide vaccine (PPSV), influenza vaccine, and tetanus-diphtheriaacellular pertussis (Tdap) vaccination rates and intervention costs from a randomized controlled cluster trial implementing the 4 Pillars program in two U.S. cities were used. The cohort of high-risk 18-64 year-olds not receiving the intervention was assigned baseline vaccination rates for high-risk 18-64 year olds from the trial, while an identical cohort receiving the intervention had absolute increases in vaccination uptake rates for this age and risk group from the end of the two-year trial. Ranges of vaccine coverage in both intervention and non-intervention cohorts came from uptake rates in different trial sites. Because our unit of analysis was the cohort and overall vaccine protection within the cohort, we assumed that the probability of receiving one vaccine was independent of receiving the others and, based on these probabilities, portions of the cohort could potentially receive one, two, or three vaccines, or none at all. Despite knowing that persons receiving one vaccine are more likely to receive another, we assumed this independence because there is no cross protection from one vaccine to another. Thus, protection afforded by any one vaccine is solely determined by the proportion of the population receiving that vaccine. Based on current guidelines regarding pneumococcal immunization, we assumed that immunocompromised persons receive both PPSV and the 13-valent pneumococcal conjugate vaccine (PCV13), while the remaining high-risk persons received PPSV only.





Table 1 lists model parameter base case values and their corresponding ranges examined in sensitivity analyses. Each parameter was varied individually in 1-way sensitivity analysis over the ranges shown in Table 1. All parameters were also simultaneously varied over their distributions 5000 times in a probabilistic sensitivity analysis, with results depicted in Fig. 2 as acceptability curves. As the original study did not collect illness rate data, illness attack rates for unvaccinated high-risk individuals 18-64 years of age were derived from the medical literature; whereas illness risk for vaccinated individuals was calculated as each illness's attack rate in the unvaccinated multiplied by 1 minus vaccine effectiveness. Age-specific estimates of vaccine effectiveness for influenza and Tdap were obtained from the medical literature. For pneumococcal vaccine, ageand comorbidity-specific Delphi expert panel estimates [10] of yearly effectiveness - PPSV against invasive pneumococcal disease (IPD), PCV13 against IPD, and PCV13 against non-bacteremic pneumococcal pneumonia (NBP) - were each averaged over a 10-year period, with overall effectiveness calculated as illness-specific vaccine effectiveness multiplied by the vaccine-specific pneumococcal illness serotype prevalence to calculate illnessspecific vaccine effectiveness against all serotypes, adjusted for recent pneumococcal vaccine trial results [11]. In the analysis, we assume that PPSV is ineffective against NBP, based on Delphi panel estimates [10], which could bias against interventions to improve vaccination rates. Over the model 10-year time horizon, program-related improvement in vaccination rates was assumed to be constant. However, these improvements were varied widely in sensitivity analyses to test this assumption, and to determine what levels of improvement would be necessary for the program to be favored.

In the decision analysis model (Fig. 1), when considering public health outcomes, influenza outcomes included illness requiring no treatment, outpatient treatment, hospitalization, or death, based on probabilities from the literature [12]. Outcomes for pneumococcal disease included IPD and NBP, with risks of disability and mortality for each. NBP cases could either be treated as outpatient or inpatient, while all IPD cases were assumed to be hospitalized [13]. Individuals could have mild, moderate, or severe pertussis; with severe pertussis, there were additional risks of mortality or encephalopathy [14, 15]. Diphtheria and tetanus outcomes were not included in the analysis due to rarity of those diseases. Model outputs for vaccine-preventable illness, hospitalization, and death were included as proportions of the cohort, which are presented as percentages and as likelihoods per 100,000 in the cohort.

In the cost effectiveness analysis, vaccine-preventable illnesses occurring over the 10-year model time horizon had effectiveness modeled as lifetime per-person losses in quality adjusted life years (QALY) due to those illnesses; disability and death resulted in QALY losses based on the discounted life expectancy of the cohort. Costs of the 4 Pillars Program were calculated based on questionnaire data completed by study sites on personnel time and materials costs devoted to the program during its implementation and maintenance phases, which totaled \$1.78 per eligible patient. These costs, which included estimates of time required for all components of the 4 Pillars, including physician immunization champions, were varied over ranges based on differences in observed site-specific costs and on alternative costing assumptions. These costs varied from \$1700-\$5400 per center per year, and are further enumerated in Additional file 1: Table S1. All other costs and quality of life utilities were obtained from the medical literature and U.S. databases [11, 12, 14, 16-18]. All costs were inflated as necessary to 2015 U.S. dollars using the Consumer Price Index. In accordance with recently updated recommendations for cost-effectiveness analysis [19], our results include both third party payer and societal perspectives. Third party payer perspective costs include direct medical costs from illness outcomes, vaccinations and intervention program, and cost of death; whereas societal perspective costs additionally included the costs of lost productivity from illness, disability, and death. Cost-effectiveness results were calculated by comparing each strategy's per person total costs for the intervention, vaccination, and illness and effectiveness in quality adjusted life years to determine the incremental cost and incremental effectiveness between strategies. Dividing incremental cost by incremental effectiveness calculates the incremental cost effectiveness ratio (ICER), producing the incremental cost per quality adjusted life year gained for one strategy compared to the other.

#### Results

The model demonstrated substantial public health benefits of the intervention over a 10-year period for adults 18–64 years with high-risk medical conditions (Table 2). Specifically, the intervention program reduced influenza cases by 1.37% and influenza hospitalizations by 0.028%. With the intervention program, the model also predicted smaller but substantial decreases in pertussis and in pneumococcal disease.

Table 3 outlines cost-effectiveness analysis results from the model. From a third party payer perspective, considering only direct medical costs, the 4 Pillars Program per-person total vaccination and illness costs were \$1642, \$17.88 greater than no intervention, while losing 0.00063 QALYs compared with no program, thus the program had an ICER of \$28,301 per QALY gained.

Table 1 Model parameter values for high-risk adults aged 18–64 years

Parameter	Base case	Range	Source
Probabilities	%	%	
Vaccination probability with no program			
Influenza	52.1	26.4-85.7	4 Pillars™
Tdap	37.9	4.2-85.7	4 Pillars™
Pneumococcal vaccines	43.4	16.7-61.9	4 Pillars™
Absolute increase in vaccine uptake with program			
Influenza	4.7	0-15.2	4 Pillars™
Tdap	11.5	0-27.3	4 Pillars™
Pneumococcal vaccines	12.3	4.1-28.6	4 Pillars™
Vaccine effectiveness			
Influenza	59.0	20–67	[28]
Tdap (10 year average)	24.5	0–95	[29]
Pneumococcal vaccines (10 year average <sup>a</sup> )			Calculated [10, 11]
PPSV alone (pts with comorbid conditions) Against IPD	46.5	22–72	
Against NBP	0	_	
PPSV and PCV13 (immunocompromised pts) Against IPD	36.3	19–56	
Against NBP	25.8	14–40	
Pneumococcal illness serotype prevalence			
PCV13 serotypes	30.7	6.8–63	[16]
PPSV serotypes	67.6	51-82	[16]
Relative likelihood of immunocompromised given high-risk	10.7%	5-15%	[1]
Probability of illness without vaccinations (yearly)			
Influenza	6.6	3.2–10	[12]
Pertussis	0.202	0.101-0.303	[15]
IPD (pts with comorbid conditions)	0.012	0.006-0.018	[13]
IPD (immunocompromised pts)	0.074	0.037-0.111	[13]
NBP (pts with comorbid conditions)	1.44	0.72-2.16	[13]
NBP (immunocompromised pts)	9.05	4.5-13.58	[13]
Relative likelihood of outpatient treatment (vs. inpatient)	90.07	76–98	[13]
IPD disability	6.02	4–8	[13]
IPD mortality	15.9	13.8–35.2	[13]
NBP disability	3	2–4	Estimate
NBP mortality	6.3	5.3-14.3	[13]
Case-hospitalization, influenza	1.93	0.65-3.21	[12]
Case-mortality, influenza	0.134	0.04224	[12]
Outpatient influenza	62.5	38.9-86.1	[12]
Pertussis severity relative likelihood			
Mild	11	5–17	[14]
Relative likelihood of treatment (vs. no treatment)	37.2	20–55	[14]
Moderate	86	75–90	[14]
Severe (hospitalized)	3	0–6	[14]
Encephalopathy, given severe	1.43	0–3	[14]
Mortality, given severe	0.86	0–2	[14]

Table 1 Model parameter values for high-risk adults aged 18-64 years (Continued)

Contr (now year 2015)USSVaccinesInduerza10.69664-32.75[30]Tdap37.5520.84-12.01[30]PSV78.9026.60-13.0[31]PSV178.9026.61-32.03[31]Implementation program, per vaccine55.8820-30[31]Implementation program, per vaccine25.0820-30.1[31]Implementation program, per vaccine305133-457[17]Societal perspective305133-457[17]Societal perspective202411-333[17]Societal perspective212636[17]Societal perspective212636[17]Societal perspective214212-636[17]Societal perspective214212-636[17]Societal perspective214212-636[17]Societal perspective214212-636[17]Societal perspective21641412]Societal perspective216352-11,775[14]Societal perspective216216[12]Societal perspective216216[12]Societal perspective216216[12]Societal perspective216216[13]Societal perspective216216[13]Societal perspective216216[13]Societal perspective216216[13]Societal perspective131352[14]Societal pers	Parameter	Base case	Range	Source
VacchiesVacchie	Costs (base year 2015)	US\$	US\$	
Influenza1069664-3275100Tdap75302018-42.61100PRV783026.01-30100PCV131596096.1-220130Vaccine administration, per vaccine75820-30131Implementation orgam, per legible person15820-30131Mild partussis, when treated85153-457177Societal perspective80153-457177Societal perspective80131-1502177Societal perspective8031-1502177Societal perspective810310-12301141Indeparty payer perspective826130-12391141Societal perspective821322-11,775141Indeparty payer perspective821323-45,118121Indeparty payer perspective82421-416121Induca (catigationt)9442-416121Induca (catigationt)9442-416131Induca (catigationt)131134-45,118131Induca (catigationt)134134131Non-bacterenic pneumosocial dispective133,287144-44,813131Invasive pneumosocial dispective133,287144-44,813131Cost of lost poductivity133,087136,13,1006,839132Non-bacterenic pneumonia (catigatient)133,087143141Invasive pneumosocial dispective133,087143141Non-bacterenic pneumonia035,0803-06 </td <td>Vaccines</td> <td></td> <td></td> <td></td>	Vaccines			
Tapp32.5520.18-2.61[D0]PSVJ78.0078.00-13080PCV1319.2.008080Vaccine administration, per vaccine19.2.008081Implementation grogram, per eligible person305153-45717Societal parspective882441-1323(7)Moderate pertussis153-4571717Societal perspective882441-1323(7)Moderate pertussis212-636(7)17Societal perspective244212-636(7)Societal perspective78003025-11.775(14)Societal perspective2614130-12.391(14)Societal perspective8261424.1416(2)Indicator program, perspective82613025-11.775(14)Societal perspective8261424.1416(2)(14)Indicator program, perspective82613025-11.775(14)Societal perspective82613025-11.775(14)Indicator program, perspective82613025-11.775(14)Indicator program, perspective8261830-83(12)Indicator program, perspective8261830-84(12)Indicator program, perspective1212(14)Indicator program, perspective8261837-86.18(13)Indicator program, perspective13825-87(13)Indicator program, perspective13825-87(13)Non-bacteremic program, pe	Influenza	10.69	6.64-32.75	[30]
PEV78.0026.0026.00100100PC/1352.0820.0020.0080.120.0080.1Implementation program, per eligible person1.780.70-2.264 Pillas***Mild pertussis, when treatedsocial perspective88.241-1.3717.1Socieal perspective88.241-1.3717.117.1Socieal perspective88.241-1.3717.117.1Socieal perspective88.230.1-1.50217.117.1Socieal perspective78.0030.21.1.7514.117.1Socieal perspective78.0030.25.11.77514.112.1Indepart part perspective82.141.012.112.1Indepart perspective82.141.012.112.1Indepart perspective82.132.113.113.112.1Induces coupsentn94.442.113.113.113.113.1Induces coupsentn94.0053.73-46.11813.1 <td< td=""><td>Tdap</td><td>37.55</td><td>20.18-42.61</td><td>[30]</td></td<>	Tdap	37.55	20.18-42.61	[30]
PCV131960096.1-20100Vaccine administration program, per eligible person1280-30611Mild pertussis, when treated124070-226171Societal perspective805153-457(171Societal perspective805121-433171Middoatta perspective805121-636171Societal perspective42421-636(171Societal perspective8261131-1502141Societal perspective82614130-12301141Societal perspective82614130-12301141Societal perspective82614130-12301141Societal perspective82614130-12301141Inducat (outpatient)921-175141121Inducat (outpatient)921-175141121Inducat (outpatient)921220-87121Inducat (outpatient)921220-87121Inducate (outpatient)517266-57131Inducate (outpatient)510823-20,628121Non-bacteremic pneumoneccal ineumonia (outpatient)71266-657131Inducativity12987154,434-29,628121Cost of lost day of productivity1361132131Cost of lost day of productivity1582121131Integrate131132131131Integrate132132-100,839131Integrate132132132131 <td>PPSV</td> <td>78.90</td> <td>26.60-130</td> <td>[30]</td>	PPSV	78.90	26.60-130	[30]
Vecche administration, per vacche25.0820-30[31]Implementation program, per eligible person1.780.70-2.264.818."Mil pertussis, when treated35.0153-4571.71Societal perspective88241-1323177Societal perspective88241-1323177Moderare pertussis101501-1502177Third-party payer perspective240501-1502177Societal perspective82614130-12391144Societal perspective82614130-12391144Influenza (outpatient)944472-1416121Industry power perspective53.21226.065-70,818131Non-bacteremic pneumococcal disease307455,373-46,118131Non-bacteremic pneumococcal pneumonia (hospitalized)7126-857131Non-bacteremic pneumococcal pneumonia (hospitalized)71263-4329,262121Ota platinty671,226335,613-1,006,839121121Non-bacteremic pneumococcal pneumonia (hospitalized)167153.263,73-29,628121Ota platinty671,226335,613-1,006,839121121Non-bacteremic pneumococcal pneumonia (hospitalized)172,26335,613-1,006,839121Ota platinty671,226335,613-1,006,839121121Non-bacteremic pneumococcal gneumonia (hospitalized)671,226335,613-1,006,839121Non-bacteremic pneumococcal gneumonia (hospitalized)122,02124124 <t< td=""><td>PCV13</td><td>159.60</td><td>96.1-220</td><td>[30]</td></t<>	PCV13	159.60	96.1-220	[30]
Implementation program, per eligible person1.780.70-2.264 Pillars"Mill pertusis, when treatd153-45717.7Third-party paye perspective82411-12317.7Societal perspective10012-63617.7Moderate pertusis1001.50217.7Societal perspective1000.150217.7Societal perspective26104130-12.39114.4Societal perspective26204130-12.39114.4Influenza (unspective)26211.75514.4Influenza (unspective)26212.6666-79.81812.2Hondpattent)9445.312-46.11813.1Hondpattent)17.4665.337-46.11813.1Non-bacterenic pneumococcal gneumonia (outpatient)57.1026-85713.1Non-bacterenic pneumococcal pneumonia (outpatient)61.2035.613-1.00.82812.1Cost of desth61.2035.613-1.00.82812.113.1Cost of lost day of productivity61.2013.613-1.00.82812.1Influenza61.2061.2061.2014.4Moderate0.200.10.4014.1Pertusis11.113.113.113.1Influenza0.210.21.0012.113.1Influenza1.2113.113.113.1Invasive preductivity0.210.21.0013.113.1Invasive preductivity0.21.000.21.0012.1Influenza0.21.000.21.00<	Vaccine administration, per vaccine	25.08	20–30	[31]
Mild pertussis, when treatedTind party payer perspective963153-457[7]Societal perspective88241-1323[7]Moderate pertussis101212-636[7]Societal perspective10101-1502[7]Societal perspective8261932-11,775[4]Influenzal courpatient)944472-1416[2]Societal perspective82614130-12,391[1]Influenza courpatient)944472-1416[2]Perumococcal disease82128373-46,118[1]Non-bacteremic pneumococcal pneumonia (notpatient)71,4668733-26,199[3]Non-bacteremic pneumococcal pneumonia (notpatient)13,085[6,494-49,481[3]Obshilty92,097(6,494-49,481[3][3]Cost of lost day of productivity671,22633,613-1,006,839[2]Cost of lost day of productivity671,22633,613-1,006,839[2]Cost of lost day of productivity65846,3-08,60[1]Cost of lost day of productivity65846,3-08,60[1]Mild098-09,90[1][1]Moderate0810,5-09,50[1]Pertussi1111[1][1]Inspitalized0,2-0,40[1][1]Mild0,0-0,40[1][1][1]Inspitalized0,0-0,40[1][1]Inspitalized0,0-0,40[1][1]Inspitalized0,0-0,40[1] </td <td>Implementation program, per eligible person</td> <td>1.78</td> <td>0.70-2.26</td> <td>4 Pillars™</td>	Implementation program, per eligible person	1.78	0.70-2.26	4 Pillars™
Third-party payer perspective305153-457(17)Societal perspective882441-1323(17)Moderate pertussis171501-1502(17)Societal perspective1001501-1502(17)Societal perspective82614130-12,391(14)Infuenza (ourpatient)944421-1416(12)Infuenza (ourpatient)53,21226,666-79,818(12)Hordparty payer perspective53,21226,666-79,818(13)Invasive preumococcal disease17,4668733-26,199(13)Non-bacteremic pneumococcal pneumonia (hospitalized)71286-857(13)Non-bacteremic pneumococcal pneumonia (notpatient)571836-817-00,60,839(12)Obability23,98716,494-49,481(13)Cost of lost productivity17186-825(12)Cost of lost productivity18705,432-29,628(12)Unitize11153,0850,404-49,481(13)Cost of lost productivity1870,543-29,628(12)Unitize11159-235(12)12)Influenza190,1-0412]12]Influenza190,1-0412]12]Influenza190,1-0414]13]Influenza190,1-0414]13]Influenza190,1-0414]14]Influenza190,1-0414]14]Influenza190,1-0414]14] </td <td>Mild pertussis, when treated</td> <td></td> <td></td> <td></td>	Mild pertussis, when treated			
Societal perspective882441-1323(17)Moderate pertusisThird-party payer perspective20150-1502(17)Societal perspective100150-1502(17)Societal perspective28203925-11.775(14)Indreparty payer perspective28214130-12.91(14)Indreparty Dayer perspective52126666-79.818(12)Hospitalized influenza53.126666-79.818(13)Hospitalized influenza30.74515,373-46,193(13)Non-bacteremic pneumococcal pneumonia (hospitalized)7466828-857(13)Non-bacteremic pneumococcal pneumonia (notipatient)510826-857(13)Ota di day of productivity32,98716,444-49,481(13)Cost of leath15,305-40,0839(12)(12)Utilize1113,08576,543-229,628(12)Utilize1113,08510,44-49,481(13)Cost of leat productivity12016,44-49,481(13)Cost of leat productivity1308576,543-229,628(12)Utilize1113,08510,44-49,481(13)Utilize1113,08510,44-49,481(13)Cost of leat productivity1200,10412,104Utilize1111,21411,21411,214Utilize1111,21411,21411,214Indiana1211,21411,21411,214Indiana1211,21411,21	Third-party payer perspective	305	153–457	[17]
Moderate pertussisTird-party payer perspective62422-636[7]solical perspective17[7]solical perspective7850325-11.775[4]solical perspective82614130-12.391[4]Influence (outpatient)944422-1416[2]looptate of perspective32.1292.978.8[3]Penumococcal disease30.745[3,373-46,118[3]Non-bacterenic pneumococcal pneumonia (hospitalized)17.4668733-26,199[3]Non-bacterenic pneumococcal pneumonia (hospitalized)32.98764.87.292.68[3]Obsabitive51.30865.43-229.620[3][3]Cost of dath13.08565.43-229.620[2][3]Cost of dath15.308516.49.49.81[3][3]Cost of lost aly of productivity612.2635.61.91.006.839[2][2]Utimier116.2035.61.91.006.839[2][3]Indicational (hospitalized)16.72.2035.61.91.006.839[2][2]Utimier110.2010.40.10[2][2]Indicational (hospitalized)10.2010.40.10[2][3]Mil-00.40.10[3][4][3]Instructional (hospitalized)0.200.40.10[4][4]Instructional (hospitalized)0.200.40.10[4][4]Instructional (hospitalized)0.200.40.10[4][4]Instructional (hospitalized) <t< td=""><td>Societal perspective</td><td>882</td><td>441-1323</td><td>[17]</td></t<>	Societal perspective	882	441-1323	[17]
Third-party payer perspective424212-636[17]Severe1001501-1502[17]Severe68003925-11,775[14]Societal perspective82614130-12,391[14]Influenza (oupatient)944422-1416[12]Hospitalized influenza53,2126,666-79,818[13]Pneumococcal disease53,2126,666-79,818[13]Non-bacteremic pneumococcal pneumonia (hospitalized)17,46687,33-46,118[13]Non-bacteremic pneumococcal pneumonia (outpatient)29,87[13][13]Non-bacteremic pneumococcal pneumonia (hospitalized)7126-857[13]Osta of dash15,308575,43-229,628[12][13]Cost of dash of productivity61,26635,613-10,06,839[12]Cost of lost groductivity61,26635,613-10,06,839[12]Influenza15,0850.3-0.8[17]Influenza0.20.1-0.4EstimatePertusis10.20.1-0.4EstimateMild0.90.3-0.8[14][13]Mild0.90.4-0.9[14][14]Non-bacteremic pneumococcal pneumonia0.20.0-0.4[14]Pertusis111[16]Invisio0.20.0-0.4[16][16]Mild0.90.20.0-0.5[16]Invisio pneumococcal pneumonia0.20.0-0.5[16]Invisio pneumococcal pneumonia0.20.0.	Moderate pertussis			
Societal perspective100150-1502[17]Societal perspective7850325-11,775[4][Interna (ottpatter) payer perspective261312-12,31[4]Interna (ottpatter)844472-1416[12]Hospitalized influenza53,122,606-79,818[13]Non-bacteremic pneumococcal disease30,74515,373-46,118[13]Non-bacteremic pneumococcal pneumonia (hospitalized)17,46686-857[13]Non-bacteremic pneumococcal pneumonia (hospitalized)2,9876444-49,481[13]Osta of lost of op op oblicitivity13,08565,43-229,628[12]Cost of lost op op oblicitivity13,08535,613-1006,839[12]Cost of lost op of op oductivity137158-100[13]Influenza1153,0850.30,80[17]Inspitalized0,200.10,403[13][14]Indipersion0.5580.3-0,80[14][14]Indipersion0.8-0,90[14][14]Indipersion0.8-0,90[14][14]Indipersion0.8-0,90[14][14]Indipersion0.8-0,90[14][14]Indipersion0.8-0,90[14][14]Indipersion0.20.2-0,95[14]Indipersion0.20.2-0,95[14][14]Indipersion0.20.2-0,95[14][15]Indipersion0.20.2-0,95[14][15]Indipersion0.20.2-0,9	Third-party payer perspective	424	212-636	[17]
Indro-party payer perspective78503925-11,755[4]Social perspective82614130-12,391[4]Indro-pace (outpatient)944620-12,391[2]Ispitalized influenza6,060-79,818[2][2]Poeumocccal disease0,7455,373-46,118[3]Invasive pereumococcal disease11,4668733-26,199[3]Non-bacteremic pneumococcal pneumonia (hospitalized)17,466833-22,628[3]Non-bacteremic pneumococcal pneumonia (outpatient)5126-857[3]Ostor I death15,30856,543-229,628[2]Cost of death or productivity171182-223,628[2]Influenza187183-229,628[2]Cost of lost day of productivity187183-229,628[2]Influenza187183-229,628[2]Cost of lost day of productivity187183-229,628[2]Influenza187183-229,628[2]Cost of lost day of productivity187183-229,628[2]Influenza187183-229,628[2]Influenza187183-229,628[2]Influenza187183-229,628[2]Influenza187183-229,628[3]Influenza012183-229,628[3]Influenza187183-229,628[3]Influenza187183-229,628[3]Influenza183193-20,628 <t< td=""><td>Societal perspective</td><td>1001</td><td>501-1502</td><td>[17]</td></t<>	Societal perspective	1001	501-1502	[17]
Third-party payer perspective78503925-11,75[4]Societal perspective82614130-12,391[4]Influenza (outpatient)94472-1416[2]Hospitalized influenza024062606-79.818[1]Poeumococcal disease30,74515,373-46,118[1]Invasive pneumococcal preumonia (hospitalized)17,4668733-26,199[1]Non-bacteremic pneumococcal pneumonia (outpatient)571286-857[1]Disbility32,98716,494-49,481[1]Cost of death153,08576,543-229,628[12]Cost of death16,192153,08516,294-29,628[12]Cost of death16,192153,08516,303[12]Cost of death16,29212][1][1]Cost of lost productivity187158-233[12]Influenza11159,1282[1][1]Influenza1111[1][1]Influenza11159,1282[1][1]Influenza1113[1][1]Influenza1113[1][1]Influenza1113[1][1]Influenza1213[1][1]Influenza1213[1][1]Influenza1213[1][1]Influenza1213[1][1]Influenza1213[1][1]Influenza1213[1][1]<	Severe pertussis			
Societal perspective82614130-12,391[4]Influenza (outpatient)944472-1416[2]Hospitalized influenza53,21226,606-79,818[2]Preturcoccal disease30,74515,373-46,118[3]Non-bacteremic pneumococcal pneumonia (nospitalized)30,7468733-26,199[3]Non-bacteremic pneumococcal pneumonia (nospitalized)571286-857[3]Non-bacteremic pneumococcal pneumonia (nospitalized)571286-857[3]Disability10316,944-49,481[1]Cost of death153,08576,543-229,628[12]Cost of lost productivity671,226335,613-1,006,839[12]Cost of lost day of productivity187158-223[12]Influenza152,0850.3-0.8[17]Vibriter0,200.1-0.4EstimateInfluenza0,20.1-0.4EstimateVibriter0,200.1-0.4[14]Mid0,90.4-0.99[14]Moderate0,850.5-0.95[14]Incephalopathy0,200.5-0.95[14]Non-bacteremic pneumococcal pneumonia[14][14]Non-bacteremic pneumococcal pneumonia[14][14]Invasive pneumococcal pneumonia0.20.55[14]Invasive pneumococcal insease0.20.40[21]Invasive pneumococcal insease0.20.55[21]Invasive pneumococcal insease0.20.55[21]Invasive pn	Third-party payer perspective	7850	3925-11,775	[14]
Influenza (outpatient)944472-1416[12]Hospitalized influenza5,32122,6606-79,818[12]Pneumoccccal disease3,7451,5373-46,118[13]Invasive pneumococcal pneumonia (hospitalized)17,4668733-26,199[13]Non-bacteremic pneumococcal pneumonia (outpatient)571286-857[13]Disability3,298716,494-49,481[13][12]Cost of death153,0856,543-229,628[12]Cost of lost productivity671,226356,13-106,839[12]Cost of lost op oductivity187158-232[12]Cost of lost op oductivity0,212158-232[12]Utilities187158-23[12]Utilities1870,3-0.8[17]Influenza0,2120,3-0.8[17]Mild0,90,3-0.8[14]Moderate0,90,1-0.4Estimatepertussis140,90,9-0.9[14]Inspitalized0,90,0-0.9[14]Nor-bacteremic pneumococcal pneumonia0,20,0-0.9[14]Severe0,20,0-0.9[14]Inspitalized0,20,0-0.5[14]Nor-bacteremic pneumococcal disease0,20,0-0.5[32]Jupptient0,20,0-0.5[32]Inspitality post pneumococcal disease0,40,2-0.6[31]Inspitality post pneumococcal disease0,40,2-0.6[31]Inspitality pneumococcal disease </td <td>Societal perspective</td> <td>8261</td> <td>4130-12,391</td> <td>[14]</td>	Societal perspective	8261	4130-12,391	[14]
Hsspitalized influenza53,2126,606-79,818[12]Pneumococcal disease30,74515,373-46,118[13]Invasive pneumococcal pneumonia (hospitalized)17,4668733-26,199[13]Nombacteremic pneumococcal pneumonia (outpatient)57126-857[13]Disbility32,98716,494-49,418[13]Cost of death13,08565,543-229,628[12]Cost of death671,22635,613-1006,839[12]Cost of death y of productivity1718235,613-1006,839[12]Cost of day of productivity1718218-223[12]Utilities118235,613-1006,839[12][12]Utilities118218-23[12][12]Utilities11218[12][12][12]Influenza010-0418[13][13]Norbacteremic pneumococcal pneumonia0.5580.3-0.8[14][13]Mild0.90.4-0.99[14][14][14]Inderat0.80.5-0.95[14][14][14]Inderative pneumococcal pneumonia0.20.4-0.91[14][14]Interprint0.20.400.5[14][15]Inderative pneumococcal pneumonia0.20.5[14][15]Interprint0.20.40.4[14][15]Interprint0.20.40.5[16][16]Interprint0.20.5<	Influenza (outpatient)	944	472-1416	[12]
Pre-umococcal disease           Invasive pneumococcal disease         30,745         15,373-46,118         [13]           Invasive pneumococcal pneumonia (hospitalized)         17,466         8733-26,199         [13]           Isability         32,987         16,494-49,481         [13]           Disability         153,085         76,543-229,628         [12]           Cost of lost productivity         671,226         335,613-1,006,839         [12]           Cost of lost productivity         187         158-223         [12]           Cost of lost productivity         030,80         [13]         [14]           Influenza         1.2         1.2         [14]           Influenza         0.2         0.2         0.2         [14]           Indecate         0.2         0.2         0.2         <	Hospitalized influenza	53,212	26,606-79,818	[12]
Invasive pneumococcal disease30,74515,373-46,118[3]Non-bacteremic pneumococcal pneumonia (hospitalized)17,4668733-26,199[13]Disability280-857[13][13]Ost of death153,08576,543-229,628[12]Cost of lost productivity671,226335,613-1,006,839[12]Cost of lost day of productivity187158-223[12]Cost of lost day of productivity0580.3-0.8[17]Utilities5580.3-0.8[17]Influenza0.5580.3-0.8[14]Mild0.90.8-0.99[14]Moderate0.850.75-0.95[14]Severe0.810.6-0.9[14]Incephalopathy0.20-0.4[14]Incephalopathy0.20.0-0.5Estimate [32]Invasive pneumococcal disease0.20.0-0.5[14]Invasive pneumococcal disease0.20.0-0.5[14]Invasive pneumococcal disease0.20.0-0.5[14]Invasive pneumococcal disease0.20.0-0.5[14]Invasive pneumococcal disease0.20.0-0.5[16]Invasive pneumococcal disease0.20.0-0.5[16]Invasive pneumococcal disease0.40.2-0.6[16]Invasive pneumococcal disease0.40.2-0.6[16]Invasive pneumococcal disease0.40.2-0.6[16]Invasive pneumococcal disease0.40.2-0.6[16]Invasive pne	Pneumococcal disease			
Non-bacteremic pneumonococcal pneumonia (hospitalized)17,4668733-26,199[3]Non-bacteremic pneumonococcal pneumonia (outpatient)571286-857[3]Disability32,98716,494-49,481[3]Cost of death153,08576,543-229,628[12]Cost of lost productivity671,226335,613-1,006,839[12]Cost of lost of productivity187158-223[12]Cost of lost day of productivity18703-0.8[17]Utilities0,1240,200,1-0.4EstimateUtilities0,1240,200,1-0.4[14]Hospitalized0,20,1-0.4[14]Mild0,90,8-0.99[14]Moderate0,810,6-0.99[14]Severe0,810,6-0.9[14]Inpatient0,20,0-4[15]Inpatient0,20,0-5Estimate [32]Outpatient in pneumococcal disease0,20,0-5[16]Invasive pneumococcal disease0,20,0-5[16]Disability post pneumococcal disease0,20,0-6[16]Disability post pneumococcal disease0,20,0-5[16]Disability post pneumococcal disease0,2<	Invasive pneumococcal disease	30,745	15,373-46,118	[13]
Non-bacteremic pneumonoccal pneumonia (outpatient)571286-857[13]Disability16,494-49,481[13]Cost of death153,08576,543-229,628[12]Cost of lost productivity671,226335,613-1,006,839[12]Cost of lost day of productivity187158-223[12]Cost of lost day of productivity05580.3-0.8[17]Utilities0.1040.1-0.4EstimateVitilities0.20.1-0.4EstimateMild0.90.8-0.99[14]Moderate0.810.6-0.9[14]Severe0.810.6-0.9[14]Incephalopathy0.20-0.4[14]Incephalopathy0.20-0.5Stimate [32]Outpatient0.20-0.5Stimate [32]Invasive pneumococcal disease0.20.05Stimate [32]Disability post pneumococcal disease0.20.05Stimate [32]Disability post pneumococcal disease0.20.05Stimate [33]Disability post pneumococcal disease0.20.05Stimate [33]Disability post pneumococcal disease0.40.20.5Stimate [33]Disability post pneumococcal disease0.40.20.05Stimate [33]Disability post pneumococcal disease0.40.20.6Stimate [33]Disability post pneumococcal disease0.40.20.6Stimate [33]Disability post pneumococcal disease0.40.20.6Stim	Non-bacteremic pneumococcal pneumonia (hospitalized)	17,466	8733-26,199	[13]
Disability32,98716,494–49,481[13]Disability153,08576,543–229,628[12]Costolost productivity671,226335,613–1,006,839[12]Costolost day of productivity187158–223[12]Utilities1158–223[12]Utilities1158–223[13]Influenza155,580.3–0.8[17]Nutpatient0.5580.3–0.8[17]Hogitalized0.50.1–0.4EstimatePertussis10.90.4–0.9[14]Severe0.810.75–0.95[14]Severe0.810.6–0.9[14]Inderate0.810.6–0.9[14]Inpatient0.20.4[15]Inpatient0.20.4[2]Inpatient0.20.5[2]Invasive pneumococcal disease0.20.5[2]Disability post pneumococcal disease0.40.2–0.6[2]Disability post pneumococcal disease0.40.2–0.6[2]Disability post pneumococcal disease0.40.2–0.6[3]Disability post pneumococcal disease0.40.4[3]Disability post pneumococcal disease0.40.2–0.6[3]Disability post pneumococcal disease0.40.2–0.6[3]Disability post pneumococcal disease0.40.2–0.6[3]Disability post pneumococcal disease0.40.2–0.6[3]Disability post pneumococcal disease <td>Non-bacteremic pneumococcal pneumonia (outpatient)</td> <td>571</td> <td>286-857</td> <td>[13]</td>	Non-bacteremic pneumococcal pneumonia (outpatient)	571	286-857	[13]
Cost of death153,08576,543-229,628[12]Cost of lost productivity671,226335,613-1,006,839[12]Cost of lost day of productivity187158-223[12]Utilities151158-223[12]Utilities1510.20.3-0.8[17]Influenza0.20.1-0.4EstimateVertussis0.20.1-0.4[14]Mild0.90.8-0.99[14]Moderate0.850.6-0.9[14]Severe0.810.6-0.9[14]Indeatorie pneumococcal pneumonia0.20-0.5[14]Inpatient0.20.1-0.4[14]Norsie pneumococcal disease0.20.0-0.5[16]Disability post pneumococcal disease0.20.20.5[21]Disbulity post pneumococcal disease0.40.2-0.6[21]Disbulity post pneumococcal disease0.40.2[21]Disbulity post pneumococcal disease0.40.4[21]	Disability	32,987	16,494–49,481	[13]
Cost of lost productivity671,26335,613-1,006,839[12]Cost of lost day of productivity187158-223[12]Utilities1580.3-0.8[17]Influenza0.5580.3-0.8[17]Votpatient0.20.1-0.4EstimatePertussis10.20.1-0.4[14]Mild0.90.8-0.99[14]Moderate0.810.6-0.9[14]Severe0.810.6-0.9[14]Incephalopathy0.20-0.4[14]Nor-bacteremic pneumococcal pneumonia0.20-0.5Estimate [32]Inpatient0.20.20.5[14]Invasive pneumococcal disease0.20.2[14]Disability post pneumococcal disease0.20.2[32]Disability post pneumococcal disease0.20.2[32]Disability post pneumococcal disease0.40.2[32]Disability post pne	Cost of death	153,085	76,543–229,628	[12]
Cost of lost day of productivity187158-223[12]Utilities <td>Cost of lost productivity</td> <td>671,226</td> <td>335,613-1,006,839</td> <td>[12]</td>	Cost of lost productivity	671,226	335,613-1,006,839	[12]
Utilities         Influenza         Outpatien1       0.558       0.3–0.8       [17]         Hospitalized       0.2       0.1–0.4       Estimate         Pertussis       0.2       0.4–0.9       [14]         Mild       0.9       0.8–0.99       [14]         Moderate       0.85       0.5–0.95       [14]         Severe       0.81       0.6–0.9       [14]         Incephalopathy       0.2       0–0.4       [14]         Incephalopathy       0.2       0–0.4       [14]         Inpatient       0.2       0–0.4       [14]         Inpatient       0.2       0–0.4       [14]         Invoive pneumococcal pneumonia       1       [14]       [16]         Invoive pneumococcal disease       0.2       0–0.4       [14]         Invoive pneumococcal disease       0.2       0–0.5       Estimate [32]         Disability post pneumococcal disease       0.2       0–0.5       [32]         Disability adjusted life years lost)       04LY       0–0.4       [14]	Cost of lost day of productivity	187	158-223	[12]
Influenza       0.dtpatient       0.3-0.8       [17]         Outpatient       0.2       0.1-0.4       Estimate         Pertussis       0.2       0.1-0.4       Estimate         Mild       0.9       0.8-0.99       [14]         Moderate       0.85       0.75-0.95       [14]         Severe       0.81       0.6-0.9       [14]         Incephalopathy       0.2       0.4-0.4       [14]         Incephalopathy       0.2       0.4-0.4       [14]         Inpatient       0.2       0.4-0.4       [14]         Inpatient       0.2       0.4-0.4       [14]         Inpatient       0.2       0.4-0.4       [14]         Invasive pneumococcal pneumonia       1       [14]       [14]         Invasive pneumococcal disease       0.2       0.4-0.4       [14]         Invasive pneumococcal disease       0.2       0.4-0.4       [21]         Invasive pneumococcal disease       0.2       0.4-0.5       [32]         Invasive pneumococcal disease       0.4       0.4       0.4       [34]	Utilities			
□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□	Influenza			
Hospitalized0.20.1–0.4EstimatePertussisNild0.90.8–0.9914Mild0.90.8–0.991414Moderate0.850.75–0.9514Severe0.810.6–0.914Encephalopathy0.20-0.414Number of perumococcal pneumonia0.20-0.414Inpatient0.20-0.5Estimate [32]Number of perumococcal disease0.20.7–1Estimate [32]Invasive pneumococcal disease0.40.2–0.6Estimate [33]Disbility post pneumococcal disease0.40.2–0.6Estimate [33]Invasive pneumococcal disease0.40.20.2Invasive pneumococcal disease0.40.20.2Invasive pneumococcal disease0.40.20.2Invasive pneumococca	Outpatient	0.558	0.3–0.8	[17]
Pertussis       Nild       0.9       0.8–0.99       [14]         Moderate       0.85       0.75–0.95       [14]         Severe       0.81       0.6–0.9       [14]         Encephalopathy       0.2       0–0.4       [14]         Noterateremic pneumococcal pneumonia       0.2       0–0.4       [14]         Inpatient       0.2       0–0.4       [14]         Outpatient       0.2       0–0.4       [14]         Invasive pneumococcal disease       0.2       0–0.5       Estimate [32]         Disbility post pneumococcal disease       0.2       0–0.5       Estimate [33]         Disbility post pneumococcal disease       0.4       0.2–0.6       Estimate [33]	Hospitalized	0.2	0.1-0.4	Estimate
Mild       0.9       0.8-0.99       [14]         Moderate       0.85       0.75-0.95       [14]         Severe       0.81       0.6-0.9       [14]         Incephalopathy       0.2       0-0.4       [14]         Inpatient       0.2       0-0.4       [14]         Inpatient       0.2       0-0.4       [14]         Invasive pneumococcal pneumonia       0.2       0-0.5       Estimate [32]         Invasive pneumococcal disease       0.2       0.7-1       Estimate [32]         Diability post pneumococcal disease       0.2       0-0.5       [32]         Diability post pneumococcal disease       0.4       0.2-0.6       Estimate [33]         Diability content and beta different and beta d	Pertussis			
Moderate0.850.75-0.95[14]Severe0.810.6-0.9[14]Encephalopathy0.20-0.4[14]N-bacteremic pneumococcal pneumonia0.20-0.4[14]Inpatient0.20-0.5Estimate [32]Outpatient0.90.7-1Estimate [32]Invasive pneumococcal disease0.20-0.5[32]Disability post pneumococcal disease0.40.2-0.6Estimate [33]Disability adjusted life years lost)0.4LY0.4LY[14]	Mild	0.9	0.8–0.99	[14]
Severe         0.81         0.6–0.9         [14]           Encephalopathy         0.2         0–0.4         [14]           Non-bacteremic pneumococcal pneumonia         0.2         0–0.4         [14]           Inpatient         0.2         0–0.4         [14]           Outpatient         0.2         0–0.5         Estimate [32]           Invasive pneumococcal disease         0.9         0.7–1         Estimate [32]           Invasive pneumococcal disease         0.2         0–0.5         [32]           Disability post pneumococcal disease         0.4         0.2–0.6         Estimate [33]           Disutilities (quality adjusted life years lost)         QALY         QALY         [14]	Moderate	0.85	0.75-0.95	[14]
Encephalopathy       0.2       0-0.4       [14]         Non-bacteremic pneumococcal pneumonia       0.2       0-0.5       Estimate [32]         Inpatient       0.2       0-0.5       Estimate [32]         Outpatient       0.9       0.7-1       Estimate [32]         Invasive pneumococcal disease       0.2       0-0.5       [32]         Disability post pneumococcal disease       0.4       0.2-0.6       Estimate [33]         Disutilities (quality adjusted life years lost)       QALY       QALY       [14]	Severe	0.81	0.6–0.9	[14]
Non-bacteremic pneumococcal pneumonia       0.2       0-0.5       Estimate [32]         Inpatient       0.9       0.7-1       Estimate         Invasive pneumococcal disease       0.2       0-0.5       [32]         Disability post pneumococcal disease       0.4       0.2-0.6       Estimate [33]         Disutilities (quality adjusted life years lost)       QALY       QALY	Encephalopathy	0.2	0-0.4	[14]
Inpatient0.20-0.5Estimate [32]Outpatient0.90.7-1EstimateInvasive pneumococcal disease0.20-0.5[32]Disability post pneumococcal disease0.40.2-0.6Estimate [33]Disutilities (quality adjusted life years lost)QALYQALY	Non-bacteremic pneumococcal pneumonia			
Outpatient0.90.7–1EstimateInvasive pneumococcal disease0.20–0.5[32]Disability post pneumococcal disease0.40.2–0.6Estimate [33]Disutilities (quality adjusted life years lost)QALYQALY	Inpatient	0.2	0–0.5	Estimate [32]
Invasive pneumococcal disease0.20-0.5[32]Disability post pneumococcal disease0.40.2-0.6Estimate [33]Disutilities (quality adjusted life years lost)QALYQALY	Outpatient	0.9	0.7–1	Estimate
Disability post pneumococcal disease     0.4     0.2–0.6     Estimate [33]       Disutilities (quality adjusted life years lost)     QALY     QALY	Invasive pneumococcal disease	0.2	0–0.5	[32]
Disutilities (quality adjusted life years lost) QALY QALY	Disability post pneumococcal disease	0.4	0.2–0.6	Estimate [33]
	Disutilities (quality adjusted life years lost)	QALY	QALY	6
lliness death (discounted) 10.25 5–15 [18]	Illness death (discounted)	10.25	5–15	[18]

 Table 1 Model parameter values for high-risk adults aged 18–64 years (Continued)

Parameter	Base case	Range	Source
Durations (days lost due to illness) Illness duration (days)			
Influenza	Days	Days	
Outpatient	4	1–8	[12]
Hospitalized	24	15–35	[12]
Pertussis	87	68–107	[14]
Non-bacteremic pneumococcal pneumonia			
Inpatient	27	18–38	[34]
Outpatient	18	11–26	[34]
Invasive pneumococcal disease	27	18–38	[34]

Tdap Tetanus, diphtheria, pertussis vaccine, IPD Invasive pneumococcal disease, NBP Non-bacteremic pneumococcal pneumonia, PCV13 13-valent pneumococcal conjugate vaccine, *PPSV* Pneumococcal polysaccharide vaccine <sup>a</sup> Versus vaccine serotype



willingness to pay (or acceptability) thresholds when all parameters are varied simultaneously over distributions: a third-party payer perspective, **b** societal perspective

Table 2 Public health outcome predictions - vaccination

programs in high-risk adults aged 18–64 years				
	Strategy (cases per 100	),000)		
	4 Pillars Program	No Program		
Influenza				
Cases	32,898	34,270		
Hospitalizations	679	707		
Deaths	44	46		
Pertussis				
Cases	1759	1815		
Severe Cases	53	54		
Deaths	0.454	0.468		
Pneumococcal Disease				
IPD cases	162	168		
IPD deaths	26	27		
NBP hospitalized	1898	1926		
NBP outpatient	17,226	17,479		
NBP deaths	119	121		

IPD Invasive pneumococcal disease, NBP Nonbacteremic pneumococcal pneumonia

From a societal perspective, adding lost productivity costs, the 4 Pillars Program had per-person total costs that were \$31.15 less than no program while remaining more effective, thus dominating the no program strategy.

When varying each parameter individually in 1-way sensitivity analysis over the ranges shown in Table 1, the intervention program remained favored from both third party and societal perspectives with each individual parameter variation when using a \$100,000/QALY threshold, a commonly cited U.S. benchmark [20]. If the program was completely ineffective at increasing influenza vaccination rates or if influenza vaccine effectiveness was 20% yearly throughout the 10-year time horizon (base case 59%), then the program cost about \$75,000 per QALY gained from a third-party payer perspective; these 2 parameters, both related to influenza vaccination, were the most sensitive to variation. With individual variation of all other parameters over clinically plausible ranges as listed in Table 1, model results were robust, with the intervention strategy remaining favored throughout.

Probabilistic sensitivity analysis results, where all parameters were simultaneously varied over distributions, are depicted in Fig. 2 as acceptability curves. At a \$100,000/QALY gained threshold, the 4 Pillars Program was favored in 83.3% of the model iterations from a third party perspective and in 96.2% of model iterations from a societal perspective. From a societal perspective, the program was cost saving and more effective than no program in 75.7% of model iterations.

## Discussion

Our analysis suggests that implementing an intervention program, such as the 4 Pillars Program, to increase vaccination uptake prevented more illness and was likely economically favorable in an 18-64 year old adult population with immunocompromising conditions or other comorbid conditions that confer a high risk of vaccinepreventable disease. From a third-party payer perspective considering direct medical costs, the incremental cost-effectiveness ratio of \$28,301/QALY gained with program use was well within the benchmark \$100,000/ QALY gained threshold for economic favorability; [20] from a societal perspective that additionally considered lost productivity costs, the intervention program was less costly and more effective than no intervention; i.e., a potentially cost-saving intervention that improves health outcomes. Results were robust in sensitivity analyses, with no individual parameter variation causing the intervention to cost more than \$100,000 per QALY gained and simultaneous variation of all parameters showing that the intervention was highly likely to be favored over no intervention.

Currently, the proportion of adults with high-risk conditions in the U.S. ranges from 12.4% in the 19–24 yearold age group to 30.6% in persons 50–64 years of age [1]. These proportions are expected to grow as obesity rates continue to climb, with their attendant increases in diabetes, cardiovascular disease, and other obesityrelated diseases. A practice-based intervention, such as the 4 Pillars Practice Transformation Program, is an

Table 3 Cost-effectiveness analysis of 4 Pillars Transformation Program in high-risk adults aged 18-64 years

Strategy	Cost per person	Incremental Cost	Effectiveness (QALY)	Incremental Effectiveness (QALY)	ICER <sup>a</sup> (\$/QALY)
3rd Party Payer Pe	erspective				
No Program	\$1624.44	_	-0.02808		
4 Pillars	\$1642.32	\$17.88	-0.02744	0.00063	\$28,301
Societal Perspectiv	ve				
4 Pillars	\$3781.77	_	- 0.02744		
No Program	\$3812.92	\$31.15	-0.02808	-0.00063	Dominated <sup>b</sup>

<sup>a</sup>ICER = Incremental Cost-Effectiveness Ratio

<sup>b</sup>Costs more and less effective when compared to alternate strategy

excellent method to reach high-risk groups, because their chronic conditions typically increase the frequency with which they receive medical care. The modeled public health impact of the intervention program is notable, with substantial reductions in influenza cases and hospitalizations and in pneumococcal illness. This combination of public health benefit and economical reasonableness suggest that quality improvement efforts to increase high-risk adult vaccinations using the 4 Pillars Program are a worthwhile investment.

Many cost-effectiveness analyses of vaccine strategies can be found in the literature, mostly highly favorable toward vaccination, but fewer consider the costeffectiveness of intervention programs designed to improve vaccination rates. Analyses examining the costeffectiveness of vaccine uptake intervention programs mainly focused on adults aged 65 and older [9, 21–23]. One study compared the same 4 Pillars intervention in this analysis while the others examined different hypothetical programs of varying intensity in an elderly, minority population. These decision analysis-based studies found an increase in incremental effectiveness and slightly higher incremental costs when compared to no intervention, resulting in ICERs well below a \$50,000/QALY gained threshold, indicating economic favorability.

#### Strengths and limitations

This study is based on clinical trial results and incorporates both third-party and societal perspectives per recent guidelines [19]. All decision analyses and their results are subject to the parameters selected, although results were robust in 1-way and probabilistic sensitivity analyses. Influenza vaccination uptake and effectiveness were most sensitive to variation; thus, factors that interfere with program-related improvements in influenza vaccine uptake or diminish influenza vaccine effectiveness could impact the cost-effectiveness of the intervention. However, model results were not substantially affected by individual variation of all other parameter values, with the intervention remaining the favored strategy with individual and collective parameter variation. Another limitation is that we modeled the probability of receiving one vaccine as independent of receipt of other vaccines, in keeping with an overall public health impact perspective. In addition, we cannot separate the impact of each of the 4 Pillars. While the 4 Pillars program does allow practices to implement only those components of the program that each practice feels will be implementable and successful, studies have shown that implementation of only one or a relative few of the those components will not lead to success [24-26]. Finally, we assume that the pneumococcal polysaccharide vaccine is ineffective in preventing pneumococcal non-bacteremic pneumonia, which could be a controversial contention

[27]. However, if this vaccine is effective against NBP, the intervention becomes even more favorable compared to no program.

#### Conclusion

The 4 Pillars Practice Transformation Program is a costeffective or cost-saving strategy, depending on the perspective taken, for averting vaccine preventable diseases in adults aged less than 65 years with medical conditions that place them at higher risk for influenza complications.

#### **Additional file**

Additional file 1: Table S1. Description of data: Summary of intervention cost by center. (DOCX 17 kb)

#### Abbreviations

CDC: Centers for Disease Control and Prevention; HIV: human immunodeficiency virus; ICER: Incremental cost effectiveness ratio; IPD: Invasive pneumococcal disease; NBP: Non-bacteremic pneumococcal pneumonia; PCV13: 13-valent pneumococcal conjugate vaccine; PPSV: 23-valent pneumococcal polysaccharide vaccine; QALY: Quality- adjusted life year; Tdap: Tetanus-diphtheria-acellular pertussis vaccine; U.S.: United States

#### Acknowledgements

Not applicable.

#### Funding

Supported by a grant (U01 IP000662) from the Centers for Disease Control and Prevention. The views expressed herein are those of those authors and not those of the Centers for Disease Control and Prevention. Also supported by the National Institutes of Health (UL1 RR024153 and UL1TR000005), and by the National Institute of Allergy and Infectious Diseases (R01 Al116575).

#### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request

#### Authors' contributions

ARW and KJS performed the analysis, based on data from a study by RKZ, MPN, and CJL. ARW and KJS drafted the manuscript with critical revision by RKZ, MPN, and CJL. All authors read and approved the final manuscript.

#### Ethics approval and consent to participate

Most data used in the model came from publically available and/or published data; use of this data is exempt from ethics review in the U.S. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/ index.html#46.101. However some data came from the 4 Pillars cluster randomized trial. In that study, standard informed consent procedures were followed, and trial protocols were approved by institutional review boards of the University of Pittsburgh, Baylor College of Medicine, and the Harris Health System.

#### Consent for publication

Not applicable.

#### **Competing interests**

Dr. Zimmerman and Dr. Lin have active research grants from Sanofi Pasteur, Merck & Co., Inc., and Pfizer Inc. Dr. Nowalk has received or currently receives grant funding from Merck & Co., Inc., Pfizer, Inc., and MedImmune, LLC. All other authors have no competing interests to disclose.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Author details

<sup>1</sup>Department of Medicine, University of Pittsburgh School of Medicine, 200 Meyran Ave., Suite 200, Pittsburgh, PA 15213, USA. <sup>2</sup>Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

#### Received: 10 March 2017 Accepted: 17 January 2018 Published online: 25 January 2018

#### References

- Zimmerman RK, Lauderdale DS, Tan SM, Wagener DK. Prevalence of highrisk indications for influenza vaccine varies by age, race, and income. Vaccine. 2010;28(39):6470–7.
- Centers for Disease Contol and Prevention. Adult conditions immunization schedule. National Center for Immunization and Respiratory Diseases. 2016; http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. Accesssed 15 June 2016.
- Williams WW, Lu P-J, O'Halloran A, et al. Surveillance of vaccination coverage among adult populations- United States, 2014. MMWR Surveill Summ. 2016;65(1):1–40.
- Zimmerman RK, Brown AE, Pavlik VN, et al. Using the 4 pillars practice transformation program to increase pneumococcal immunizations for older adults: a cluster-randomized trial. J Am Geriatr Soc. 2017;65(1):114–22.
- Lin CJ, Nowalk MP, Pavlik VN, et al. Using the 4 pillars<sup>™</sup> practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial. BMC Inf Dis. 2016;16(1):623.
- Nowalk MP, Lin CJ, Pavlik VN, et al. Using the 4 pillars<sup>™</sup> practice transformation program to increase adult Tdap immunization in a randomized controlled cluster trial. Vaccine. 2016;34(41):5026–33.
- Nowalk MP, Bolan N, Nutini J, et al. Success of the 4 pillars toolkit for influenza and pneumococcal vaccination in adults. J Healthc Qual. 2014; 36(6):5–15.
- Zimmerman RK, Nowalk MP, Lin CJ, et al. Cluster randomized trial of a toolkit and early vaccine delivery to improve childhood influenza vaccination rates in primary care. Vaccine. 2014;32(29):3656–63.
- Smith KJ, Zimmerman RK, Nowalk MP, Lin CJ. Cost-effectiveness of the 4 pillars practice Transormation program to improve vaccination of adults aged 65 and older. J Am Geriat Soc. 2017;65(4):763–78.
- Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307(8):804–12.
- Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New Engl J Med. 2015; 372:1114–25.
- Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–96.
- Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥ 50 years. Vaccine. 2012;30:5437–44.
- McGarry LJ, Krishnarajah G, Hill G, et al. Cost-effectiveness of tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. PLoS One. 2014;9(1):e72723.
- Masseria C, Krishnarajah G. The estimated incidence of pertussis in people aged 50 years old in the United States, 2006–2010. BMC Inf Dis. 2015;15(1):534.
- Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, populationbased surveillance. Lancet Infect Dis. 2015;15:301–9.
- Lee GM, LeBaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005;115(6):1675–84.
- 18. Arias E. United States life tables, 2011. Natl Vital Stat Rep. 2015;64(11):1–63.
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016; 316(10):1093–103.
- Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness the curious resilience of the \$50,000-per-QALY threshold. N Engl J Med. 2014; 371(9):796–7.

- Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States. BMC Public Health. 2014;14:718.
- Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis. Value Health. 2013; 16(2):311–7.
- Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Estimating the costeffectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine. 2011;29(19):3525–30.
- 24. Zimmerman RK, Moehling KK, Lin CJ, et al. Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 pillars<sup>™</sup> practice transformation program. Vaccine. 2017;35:109–17.
- Hawk M, Nowalk MP, Moehling KK, et al. Using a mixed methods approach to examine practice characteristics associated with implementation of an adult immunization intervention using the 4 pillars practice transformation program. J Healthc Qual. 2017;39(3):153–67.
- Nowalk MP, Zimmerman RK, Lin CJ, et al. Maintenance of increased childhood influenza vaccination rates 1 year after an intervention in primary care practices. Acad Pediatr. 2016;16(1):57–63.
- 27. Moberley S, Holden J, Tatham D, Andrews R. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.
- Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44.
- Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by tdap brand. J Infect Dis. 2014;210(6):942–53.
- CDC Vaccine Price List. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccinemanagement/price-list/. Accessed 26 May 2016.
- Centers for Medicare & Medicaid Services. Physician fee schedule search. www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed 15 Oct 2015.
- Sisk JE, Whang W, Butler JC, Sneller V-P, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.
- Gold MR, Franks P, McCoy K, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778–92.
- Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31(8):901–8.

# Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

